Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Low-Dose Pulsatile Interleukin-6 As a Treatment Option for Diabetic Peripheral Neuropathy.

Cox AA, Sagot Y, Hedou G, Grek C, Wilkes T, Vinik AI, Ghatnekar G.

Front Endocrinol (Lausanne). 2017 May 2;8:89. doi: 10.3389/fendo.2017.00089. eCollection 2017. Review.

2.

Regulation of LRRK2 expression points to a functional role in human monocyte maturation.

Thévenet J, Pescini Gobert R, Hooft van Huijsduijnen R, Wiessner C, Sagot YJ.

PLoS One. 2011;6(6):e21519. doi: 10.1371/journal.pone.0021519. Epub 2011 Jun 27.

3.

Chemical inducers and transcriptional markers of oligodendrocyte differentiation.

Joubert L, Foucault I, Sagot Y, Bernasconi L, Duval F, Alliod C, Frossard MJ, Pescini Gobert R, Curchod ML, Salvat C, Nichols A, Pouly S, Rommel C, Roach A, Hooft van Huijsduijnen R.

J Neurosci Res. 2010 Sep;88(12):2546-57. doi: 10.1002/jnr.22434.

PMID:
20544820
4.

Beneficial effects of r-h-CLU on disease severity in different animal models of peripheral neuropathies.

Dati G, Quattrini A, Bernasconi L, Malaguti MC, Antonsson B, Nicoletti F, Alliod C, Di Marco R, Sagot Y, Vitte PA, Hiver A, Greco B, Roach A, Zaratin PF.

J Neuroimmunol. 2007 Oct;190(1-2):8-17. Epub 2007 Aug 21.

PMID:
17714795
5.

IKK2 inhibitor alleviates kidney and wasting diseases in a murine model of human AIDS.

Heckmann A, Waltzinger C, Jolicoeur P, Dreano M, Kosco-Vilbois MH, Sagot Y.

Am J Pathol. 2004 Apr;164(4):1253-62.

6.

Phosphatidylinositol 3-kinase activity in murine motoneuron disease: the progressive motor neuropathy mouse.

Wagey R, Lurot S, Perrelet D, Pelech SL, Sagot Y, Krieger C.

Neuroscience. 2001;103(1):257-66.

PMID:
11311806
7.

An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease.

Sagot Y, Toni N, Perrelet D, Lurot S, King B, Rixner H, Mattenberger L, Waldmeier PC, Kato AC.

Br J Pharmacol. 2000 Oct;131(4):721-8.

8.

IAP family proteins delay motoneuron cell death in vivo.

Perrelet D, Ferri A, MacKenzie AE, Smith GM, Korneluk RG, Liston P, Sagot Y, Terrado J, Monnier D, Kato AC.

Eur J Neurosci. 2000 Jun;12(6):2059-67.

PMID:
10886345
9.

NGF-induced motoneuron cell death depends on the genetic background and motoneuron sub-type.

Terrado J, Monnier D, Perrelet D, Sagot Y, Mattenberger L, King B, Kato AC.

Neuroreport. 2000 May 15;11(7):1473-7.

PMID:
10841360
10.

Differential effects of neurotrophic factors on motoneuron retrograde labeling in a murine model of motoneuron disease.

Sagot Y, Rossé T, Vejsada R, Perrelet D, Kato AC.

J Neurosci. 1998 Feb 1;18(3):1132-41.

11.

Clinical and molecular aspects of motoneurone diseases: animal models, neurotrophic factors and Bcl-2 oncoprotein.

Sagot Y, Vejsada R, Kato AC.

Trends Pharmacol Sci. 1997 Sep;18(9):330-7. Review.

PMID:
9345852
12.

Injury-induced synthesis and release of apolipoprotein E and clusterin from rat neural cells.

Messmer-Joudrier S, Sagot Y, Mattenberger L, James RW, Kato AC.

Eur J Neurosci. 1996 Dec;8(12):2652-61.

PMID:
8996815
14.

GDNF slows loss of motoneurons but not axonal degeneration or premature death of pmn/pmn mice.

Sagot Y, Tan SA, Hammang JP, Aebischer P, Kato AC.

J Neurosci. 1996 Apr 1;16(7):2335-41.

15.

Bcl-2 overexpression prevents motoneuron cell body loss but not axonal degeneration in a mouse model of a neurodegenerative disease.

Sagot Y, Dubois-Dauphin M, Tan SA, de Bilbao F, Aebischer P, Martinou JC, Kato AC.

J Neurosci. 1995 Nov;15(11):7727-33.

16.

Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse.

Sagot Y, Tan SA, Baetge E, Schmalbruch H, Kato AC, Aebischer P.

Eur J Neurosci. 1995 Jun 1;7(6):1313-22.

PMID:
7582105
17.

Encapsulation of neurotrophic factor-releasing cells for the treatment of neurodegenerative diseases.

Aebischer P, Tan SA, Déglon N, Heyd B, Zurn A, Baetge E, Sagot Y, Kato A.

Restor Neurol Neurosci. 1995 Jan 1;8(1):65-6. doi: 10.3233/RNN-1995-81215. No abstract available.

PMID:
21551809
18.
19.

BDNF-mediated rescue of axotomized motor neurones decreases with increasing dose.

Vejsada R, Sagot Y, Kato AC.

Neuroreport. 1994 Oct 3;5(15):1889-92.

PMID:
7841370
20.

Long-lasting accumulation of hemopexin in permanently transected peripheral nerves and its down-regulation during regeneration.

Madore N, Sagot Y, Guinaudy MJ, Cochard P, Swerts JP.

J Neurosci Res. 1994 Oct 1;39(2):186-94.

PMID:
7837288
21.

Up-regulation of clusterin (apolipoprotein J) and apolipoprotein E in cultured rat spinal cord neurones.

Messmer S, Mattenberger L, Sagot Y, Kato AC, James RW.

Schweiz Arch Neurol Psychiatr (1985). 1994;145(3):20-1. No abstract available.

PMID:
7533930
22.

Hemopexin is synthesized in peripheral nerves but not in central nervous system and accumulates after axotomy.

Swerts JP, Soula C, Sagot Y, Guinaudy MJ, Guillemot JC, Ferrara P, Duprat AM, Cochard P.

J Biol Chem. 1992 May 25;267(15):10596-600.

24.

Supplemental Content

Support Center